ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced two publications providing new nonclinical evidence and scientific insights into the ability of its novel stimulator of interferon genes (STING) agonist, IMGS-203, to remodel the tumor microenvironment and enhance antitumor activity in combination with the Company’s novel cytotoxic dual-specific PD-L1/PD-L2 antibody.
Read moreNews
There is always something new at ImmunoGenesis. Stay on top of the latest.
Press Releases
ImmunoGenesis to Present IND-Enabling Development Progress and Therapeutic Potential of IMGS-203, a Novel STING Agonist, at SITC 2026 Annual Meeting
ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced upcoming presentations describing the IND-enabling activities and therapeutic potential for IMGS-203, the company’s novel Stimulator of Interferon Genes (STING) Agonist, for the treatment of recurrent glioblastoma (GBM). These data will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026, at the Phoenix Convention Center in Phoenix, AZ.
Read more
ImmunoGenesis Announces Appointment of Reza Mazhari and Mike Davis to Its Board of Directors
Dr. Reza Mazhari has more than 25 years of life science operating experience in drug discovery, early-stage clinical development and business and corporate development across diverse therapeutic areas including oncology. Mr. Davis brings more than three decades of leadership experience guiding one of the world’s most respected sports organizations through periods of significant growth, innovation and organizational transformation.
Read more
ImmunoGenesis Appoints Chief Medical Officer
ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer. Dr. Dansky Ullmann will support development of the Company’s cytotoxic immune checkpoint inhibitor, IMGS-001, and ImmunoGenesis’ multi-mechanism strategy aimed at addressing the pathology of immune-excluded tumors by overcoming immune exclusion.
Read more
ImmunoGenesis Announces Poster Presentation at AACR 2026 Annual Meeting
ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced that it will present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held from April 17–22, 2026, in San Diego, CA.
Read moreKey Publications
Tumor Microenvironment Remodeling by STING Agonism Sensitizes Endothelial Cells to Cytotoxic anti-PD-L1/L2 Antibody
Salameh A, Bolli E, Iezzi M, Gagliardi C, Conti L, Cossu C, Blezinger P, Lamolinara A, Lewis A, Curran MA, Cavallo F, Pericle F. Journal of Experimental and Clinical Cancer Research. 2026.
STING-Mediated Tumor Microenvironment Remodeling: Turning Adaptive Resistance into Therapeutic Vulnerability
Boda A, Bolli E, Salameh A, Gagliardi C, Curran MA, Iezzi M, Conti L, Cavallo F, Pericle F. Frontiers in Immunology. 2026.
Abstract TPS2686: A phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of IMGS-001 in patients with relapsed or refractory advanced solid tumors.
D Hong, S Sen, C Schweizer, A Sanders, C Grimes, F Pericle, C Gagliardi, J Barlow, A Salameh, M Curran. Poster presented at: American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2025; Chicago, IL.
A potent STING agonist induces endothelial PD-L1 and enhances antitumor efficacy of a novel PD-L1/PD-L2 antibody.
A Salameh, C Gagliardi, L Conti, E Bolli, C Cossu, M Ceci, M Iezzi, F Cavallo, J Barlow, F Pericle. Poster presented at: American Association for Cancer Research Annual Meeting; April 25-30, 2025; Chicago, IL.
Development of IMGS-001, a novel anti–PD-L1/PD-L2 dual-specific, multifunctional antibody, to treat immune-excluded tumors.
C Gagliardi, A Salameh, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.
Preclinical characterization of IMGS-001, a dual-antagonist anti–PD-L1 and PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade.
A Salameh, C Gagliardi, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack, AL, Spartz, EJ, Raynor, JF, Wang, I, Olson, M, Stromnes, IM. Cell Reports. 2019.
Genomic biomarkers in relation to PD-1 checkpoint blockade response.
Seiwert, TY, Cristescu, R, Kaufman, DR, et al. Journal of Clinical Oncology. 2018.
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley, JH, Gibson, C, Yu, N, Moon, C, Murphy, E, McClanahan, T, et al. Clinical Cancer Research. 2017.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Curran, MA, Montalvo, W, Yagita, H, Allison, JP. PNAS. 2010.
Upcoming events
There are no upcoming events scheduled at this time. Sign up to receive notices about upcoming events and press releases.
Excited about what you see?
Learn more